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Abstract
CD81 (TAPA-1) is a ubiquitously expressed tetraspanin protein identified as a component of the B lymphocyte receptor
(BCR) and as a receptor for the Hepatitis C Virus. In an effort to identify trans-membrane proteins that interact with the T-cell
antigen receptor (TCR), we performed a membrane yeast two hybrid screen and identified CD81 as an interactor of the
CD3delta subunit of the TCR. We found that in the absence of CD81, in thymocytes from knockout mice, TCR engagement
resulted in stronger signals. These results were recapitulated in T cell lines that express low levels of CD81 through shRNA
mediated silencing. Increased signaling did not result from alterations in the levels of TCR on the surface of T lymphocytes.
Although CD81 is not essential for normal T lymphocyte development, it plays an important role in regulating TCR and
possibly pre-TCR signal transduction by controlling the strength of signaling. CD81 dependent alterations in thymocyte
signaling are evident in increased CD5 expression on CD81 deficient double positive (DP) thymocytes. We conclude that
CD81 interacts with the T cell receptor to suppress signaling.
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Introduction
The T cell receptor (TCR) is expressed as a multi-subunit
complex on the surface of thymocytes and T lymphocytes, made
up of eight polypeptides (TCRab, CD3ce, CD3de, TCRff).
Immunoreceptor tyrosine based activation motifs (ITAM) in the
cytoplasmic tails of these subunits provide a multiplicity of docking
sites for recruited signal-transducing proteins. Individual TCR
subunits assemble in the endoplasmic reticulum (ER) of T
lymphocytes following a defined order, whereby TCRa-CD3de
trimers and TCRb-CD3ce trimers first assemble into a six chain
complex which associates with a dimer of TCRf subunits, before
being exported to the cell surface [1]. Inactivation of the genes
encoding individual subunits of the TCR results in an arrest of
thymocyte development [2–4].
CD3d deficient thymocytes cannot receive proper TCR signals
for positive selection at the CD4+CD8+ double positive (DP) stage;
however, pre-TCR signals at the earlier CD42CD82 double
negative (DN) stage are not affected and these early thymocytes
can differentiate to the DP stage [5]. Pre-TCR signals do not
require the CD4 or CD8 co-receptors for signaling, as none are
expressed at the DN stage, while TCR signals at the DP stage are
uniquely dependent on co-receptors for positive selection signaling
[6]. Thus, CD3d is uniquely required for abTCR surface
expression and signaling but is dispensable for the function of
related multi-subunit receptors (pre-TCR and cdTCR). An
evolutionarily conserved alpha-CPM motif in the alpha subunit
of the TCR is also necessary for positive selection signaling and
linking the TCR to the CD8 co-receptor [7]. This CPM may be
important for linking the TCRa ‘‘side’’ of the TCR to CD3de
dimers, while a TCR Cb FG loop on the TCRb ‘‘side’’ may be
important for communicating with CD3ce dimers [1,8]. The co-
requirement for CD3d, the TCRa CPM and co-receptors for
positive selection signaling indicates that CD3d may be the link
between co-receptors and the TCR [9].
Here we specifically tried to identify membrane proteins that
interact with the CD3d subunit of the TCR. To do so, we used a
membrane yeast two hybrid system in which murine CD3d was
expressed as a bait protein in yeast membranes. In T lymphocytes,
TCR subunits do not individually get transported to the plasma
membrane; rather, individual subunits are retained in the ER and
only fully assembled TCR is expressed on the cell surface [1].
Because our screening strategy only involved the expression of the
CD3d subunit, it is possible that the interactions we identified in
yeast cells may be occurring in the ER or other sub-cellular
membranes.
Using this screening strategy, we identified various membrane
proteins that play a role in TCR assembly and signaling. Prime
among these molecules was CD81 (TAPA-1), which is a
ubiquitously expressed tetraspanin protein [10]. CD81 has been
identified as a component of the B lymphocyte receptor and as a
receptor for the Hepatitis C Virus [11–13]. We chose to explore
the role CD81 plays in TCR signaling because of previous reports
of its association with the CD4 and CD8 co-receptors [14]. Other
reports indicated that upon superantigen exposure, CD81 co-
localized with CD3 at the c-SMAC in the immune synapse formed
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between T and B lymphocytes [15]. Two independent groups
generated CD81 deficient mice where redundancy between CD81
and its close homolog CD82 or other tetraspanin proteins, likely
resulted in no observable phenotype [16,17]. While CD81
deficient mice were originally found not to have an in vivo T
lymphocyte development defect, we find here that developing
thymocytes receive stronger signals than WT counterparts,
resulting in an in vivo upregulation of the CD5 activation marker
at the DP thymocyte stage. Indeed, similar to earlier in vitro studies
which found that CD81 deficiency resulted in enhanced T cell
proliferation, in this study we document that CD81 deficient T
lymphocytes respond better to antibody mediated signaling.
Results
Identification of CD3d interaction partners by membrane
yeast two hybrid screening
In the present study we tried to identify membrane proteins that
participate in signal transduction by the T lymphocyte receptor
(TCR). To this end, we performed a novel membrane based yeast
two hybrid screen by using the CD3d subunit of the TCR as bait.
This screening system allowed us to identify membrane anchored
or cytoplasmic proteins that interact with this TCR subunit by
reconstituting a functional ubiquitin protein. Formation of
functional ubiquitin in turn released a membrane anchored
LexA-VP16 transcription factor into the yeast nucleus, that
enabled us to select Saccharomyces cerevisiae cells which contained
interacting bait and prey proteins (Figure S1). For screening, we
expressed C-terminal ubiquitin fused CD3d proteins, N-terminally
fused to a yeast leader peptide (for membrane insertion) from a
bait plasmid, pBT3SUC-CD3d and an N-terminal ubiquitin fused
prey cDNA library derived from human Jurkat T cell lines.
The yeast two hybrid screen was designed with 3 readouts:
growth of auxotrophic yeast cells on medium lacking histidine and
adenine and the expression of the LacZ gene. We identified 426
colonies on selective plates which also tested positive in a b-
galactosidase filter lift-off assay. We reconfirmed positive inter-
actors by independently transforming bait and prey protein
encoding plasmids into yeast cells grown on selective medium.
The identities of cDNAs identified from positive interactors in
independent testing are shown in Table 1.
Specificity of CD3d interactions in yeast cells expressing
TCR subunits
Because the CD3d subunit of the TCR is known to hetero-
dimerize with the CD3e subunit in T lymphocytes, we tested the
specificity of interaction in yeast cell membranes by confirming
that yeast cells expressing CD3d fused to the C-terminal domain of
ubiquitin (CD3d-Cub) and CD3e fused to the N-terminal domain
of ubiquitin (CD3e-Nub) could indeed grow on selective media.
While yeast cells expressing CD3d-Cub only, or CD3d-Cub
together with an unrelated prey protein did not grow, yeast cells
expressing CD3d-Cub and CD3e-NubG grew and generated
many colonies on selective plates. Next, we tested whether the
interactions of TCR subunits identified in yeast membranes are
similar to those in mouse T lymphocytes, by assessing the
interaction of CD3d-Cub with TCRa-NubG or TCRb-NubG.
In mouse DP thymocytes, CD3d forms a heterodimer with CD3e,
and then associates with TCRa in a TCRa-CD3d-CD3c trimer
and CD3d does not directly homodimerize with TCRa or TCRb
[1]. In CD3d-Cub + TCRa-NubG, or CD3d-Cub + TCRb-NubG
expressing yeast cells grown on Leu-,His-,Trp-,Ade- selective
plates, the number of colonies obtained was either zero or very
few, compared to yeast cells expressing interacting CD3d-Cub and
CD3e-NubG proteins (Table 2). We conclude that the split
ubiquitin yeast expression system can recapitulate the membrane
environment that allows TCR subunits to interact with each other,
and continued to analyze the proteins encoded by the Jurkat T
lymphocyte library that interact with CD3d-Cub. We decided to
further investigate the functional significance of the interaction
between CD3d and a clone expressing a CD81 cDNA, which was
isolated from the Jurkat T lymphocyte library and scored as a
positive interactor in our secondary screen (Table 1).
Confirmation of the interaction between CD3d and CD81
in human cell lines
We assessed whether we could recapitulate the CD3d and
CD81 interaction in mammalian cells by co-transfecting human
Table 1. The identity of cDNAs identified from positive interactors.
CLONE ID BLAST RESULT GENE ID
3A3a NM_001040200.1 Homo sapiens claudin domain containing 1 (CLDND1), transcript variant 7, mRNA.
1G6/1I8a/3I3 NM_000873.2 Homo sapiens intercellular adhesion molecule 2 (ICAM2), mRNA
1C8 NM_002208.3 Homo sapiens integrin, alpha E (ITGAE), mRNA.
1E2b/1E7 NM_021227 Homo sapiens DC2 protein (DC2), mRNA
1G4 NM_018845.1 Homo sapiens recombination activating gene 1 activating protein 1 (RAG1AP1), mRNA
3A2b NM_004221.4 Homo sapiens interleukin 32 (IL32), transcript variant 2, mRNA.
3A5b NM_025124.1 Homo sapiens transmembrane protein 134 (TMEM134), mRNA.
3A7b NM_003329.2 Homo sapiens thioredoxin (TXN), mRNA
3B3b/3K8 NM_032927.2 Homo sapiens transmembrane protein 128 (TMEM128), mRNA
3C1 NM_005745.6 Homo sapiens B-cell receptor-associated protein 31 (BCAP31), mRNA
3I1 NM_004356.3 Homo sapiens CD81 molecule (CD81), mRNA
1G1 NM_198793.2 Homo sapiens CD47 molecule (CD47), transcript variant 2, mRNA
1H4/3E1a NM_144638.1 Homo sapiens transmembrane protein 42 (TMEM42), mRNA
1J8A/1K1a/1K1b NM_014051.2 Homo sapiens transmembrane protein 14A (TMEM14A), mRNA
doi:10.1371/journal.pone.0050396.t001
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HEK293T cells with expression plasmids encoding C-terminal
Myc-epitope tagged CD3d proteins and N-terminal HA-epitope
tagged CD81 proteins. Transfected cell lysates containing CD3d
only, CD81 only, or both proteins together were immunoprecip-
itated with anti-Myc epitope specific antibodies and blotted with
anti-HA specific antibodies, revealing a specific interaction
between these proteins in human cell lines (Figure 1). Notably,
as HEK293T cells do not express the rest of the TCR subunits,
this interaction between CD3d and CD81 likely occurs in sub-
cellular membranes rather than the plasma membrane, similar to
the interactions we observed in yeast cells.
We further wanted to test the association between CD3d and
CD81 in a setting where CD3d could assemble into a TCR and be
expressed on the cell surface. To this end, we expressed all
subunits of the TCR in multi-cistronic expression plasmids in the
presence or absence of epitope tagged CD3d and CD81 in
HEK293T cells. We first assessed the cell surface expression of the
assembled TCR by flow cytometry and found that up to 40% of
transfected cells could indeed express surface TCR complexes
containing TCRb (Figure S2A). The assembly and surface
expression of TCR in HEK293T cells was specific, as cells
expressing only TCRa and TCRb or only the CD3 subunits
CD3d, CD3e, CD3c, TCRf could not express detectible levels of
TCRb on the cell surface. We next tested whether epitope tagged
CD3d subunits could assemble into multi-subunit TCR complex-
es. In fact, immunoprecipitation with anti-Myc epitope specific
antibodies followed by anti-TCRa blotting revealed that Myc-
CD3d could be found in complexes which contained TCRa (data
not shown). Finally we assembled TCR in HEK293T cells and
assessed the binding of HA-epitope tagged CD81 with Myc-
epitope tagged CD3d in these cells. Similar to the CD81-CD3d
interaction we previously observed in the absence of full TCR,
CD3d could interact with CD81 in the presence of TCR
assembled in HEK293T cells (Figure S2B). Thus, CD3d can
interact with CD81 either in the presence or absence of fully
assembled TCR.
Functional significance of the CD3d-CD81 interaction
Because the CD3d subunit of the TCR and the tetraspanin
protein CD81 could interact in membrane environments which
mimicked the T lymphocyte membrane, we wanted to determine
whether the interaction between the CD3d and CD81 has a
functional significance for TCR assembly and signaling. To this
end, we decided to downregulate CD81 expression in cell lines by
shRNA mediated expression arrest. To screen for functional
shRNAs, we overexpressed HA-epitope tagged CD81 cDNAs
along with two different shRNAs against different regions of the
CD81 cDNA in HEK293T cells and found that CD81 protein
levels were dramatically downregulated by one of these shRNAs
(sh1CD81), while CD81 levels did not decrease in cells co-
expressing an empty shRNA expression plasmid (Figure 2A).
To further assess whether the shRNA specific against the CD81
cDNA could downregulate cell surface CD81 levels expressed
from endogenous genes, we generated retroviruses expressing
shRNA either against a non-specific EGFP protein or against
CD81 (sh1CD81), and infected the mouse NIH 3T3 cell line with
these retroviruses. Analysis by flow cytometry revealed that the
surface expression of endogenous CD81 proteins were dramati-
cally reduced in cells infected with retroviruses expressing
sh1CD81 but not with shRNA against EGFP (Figure 2B).
To test the function of CD81 in T lymphocytes, we transfected
the murine CD4+CD8+ double positive VL3.3M2 cell line with
plasmids expressing sh1CD81, the shRNA previously determined
to be capable of silencing CD81 expression. The expression
construct for sh1CD81 also expressed a puromycin resistance gene
and an EGFP marker, so we identified stably transfected cells in
the presence of the antibiotic puromycin and followed CD81
expression in these cells by EGFP expression. After antibiotic
selection, VL3.3M2 cells were uniformly EGFP positive
(Figure 3A). Furthermore, compared to untransfected cells or
those stably expressing puromycin and EGFP without sh1CD81
(LMP), sh1CD81 expressing VL3.3M2 cells downregulated
surface CD81 approximately 30% as measured by the mean
fluorescence intensity of surface bound anti-CD81 antibodies in a
flow cytometer. In order to generate T cell lines that further
Table 2. CD3d interacts with TCR subunits in S. cerevisiae.
Prey 2L 2T 2LT 2LTH 2LTHA
Positive Control + + + + +
Negative Control + + + 2 2
Empty Prey + + + 2 2
TCRa + + + 2 2
TCRb + + + +/2 +/2
CD3d + + + +/2 +/2
CD3e + + + + +
Auxotrophic yeast strains transformed with a bait plasmid encoding CD3d
carrying a Leu2 gene and a prey plasmid encoding a Trp2 gene. Yeast cells
transformed only with a bait plasmid or only with a prey plasmid or with bait
and prey plasmids together could grow on Leu- or Trp- or Leu-,Trp- plates
respectively. Growth on Leu-,His-,Trp-, or Leu-,His-,Trp-,Ade- selective plates
required the interaction of the CD3d bait with the indicated prey cDNA’s.
+ denotes growth of .100 colonies and +/2 denotes growth of ,10 colonies
on the indicated plates.
doi:10.1371/journal.pone.0050396.t002
Figure 1. CD81 interacts with CD3d. HEK293T cells were transfected
with plasmids encoding CD81 protein in the presence (lane 4) or
absence of CD3d (lanes 3). Top row: Lysates from untransfected
HEK293T cells (lane 1) or transfected cells (lanes 2–4) were immuno-
precipitated with anti-Myc antibodies and immunoblotted with anti-HA
antibodies. Anti-HA immunoblot shows the presence of a 26 kD band
corresponding to the CD81 protein co-immunoprecipitated with Myc-
CD3d protein. Middle row: anti-HA immunoblot of lysates demonstrates
the expression of CD81 specifically in cells transfected with this
construct (lane 3–4). Bottom row: anti-Myc immunoblot of lysates
demonstrates the expression of CD3d in lanes 2 and 4.
doi:10.1371/journal.pone.0050396.g001
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downregulated surface CD81 expression, we generated single cell
clones from this pool of sh1CD81 expressing VL3.3M2 cells, by
limiting dilution. We identified two clones which further down-
regulated surface CD81 expression up to 60% (Figure 3B).
To ensure that sh1CD81 expression specifically silenced CD81
and not other surface T cell markers involved in TCR signal
transduction, we assessed surface TCR levels in either the stably
transfected pools or in the individual clones by anti-TCRb staining
(Figure S3A). Compared to the TCR levels in either untrans-
fected VL3.3M2 cells, or those transfected by empty shRNA
expression plasmids (LMP), stable transfected VL3.3M2 cells
which expressed sh1CD81 and silenced CD81 did not downreg-
ulate surface TCR expression. Thus, silencing CD81 in VL3.3M2
thymocytes specifically downregulates surface CD81 expression
without altering surface TCR levels. On the other hand when we
overexpressed a human CD81 cDNA in either HEK293T cells
with a reconstituted TCR, or in murine VL3.3M2 cells, we
observed a significant reduction in surface TCR expression (data
not shown). Thus overexpression of CD81 interferes with TCR
assembly while decreasing CD81 expression by shRNA mediated
knockdown has no effect on this process.
To identify the role of CD81 in TCR signaling, we stimulated
stably transfected sh1CD81 expressing VL3.3M2 cells with
different levels of surface CD81, with anti-TCRb plus anti-CD4
mAb. We assessed the intensity of TCR signaling upon antibody
crosslinking by CD69 upregulation. When we stimulated un-
transfected VL3.3M2 thymocytes, (sh1CD81) stable transfected
pools or clone2, expressing high, intermediate or low levels of
CD81 respectively, clone 2 responded by upregulating dramati-
cally more CD69, compared to either the pool of sh1CD81
silenced VL3.3M2 cells or untransfected cells (Figure 3C and
Figure S3B). Dramatically, we noticed an inverse correlation
Figure 2. CD81shRNAs knock down CD81 protein expression and surface CD81 expression. (a) HA-CD81 transfected HEK293T cells with
or without shRNA expression were solubilized in Triton X-100 detergent and resolved by reducing SDS-PAGE and blotted with anti-HA Ab. Lysates
from HEK293T cells expressing HA-CD81 alone (lane1), untransfected cells (lane 2), cells expressing HA-CD81 plus empty pLMP shRNA expression
construct (lane 3) and HA-CD81 plus sh1CD81 or sh2CD81 expressing pLMP constructs (lanes 4 and 5 respectively) were blotted with anti-HA Ab
revealing a 26 KDa HA tagged CD81 band. Equal loading was confirmed by blotting the same membrane with anti-calnexin Ab revealing a 90 KDa
calnexin band. (b) NIH3T3 cells infected with retrovirus coding shRNA against EGFP (shEGFP) (heavy dotted histogram), empty pLMP shRNA
expression construct (solid histogram) or sh1CD81 expressing pLMP construct (tinted histogram) were stained with anti-CD81 biotin followed by
streptavidin-PE. Histograms show surface CD81 levels of the cells. The relative mean fluorescence intensity (MFI) normalized to CD81 expression on
empty LMP transfected NIH3T3 cells (set to 100) is plotted as a bar graph.
doi:10.1371/journal.pone.0050396.g002
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between the level of surface CD81 expression and CD69
upregulation upon anti-TCRb and anti-CD4 mAb crosslinking.
Thus, we found that downregulating surface CD81 expression
increases the signaling intensity of CD4 co-receptor dependent
TCR in DP VL3.3M2 thymocytes.
Because CD81 is a tetraspanin protein enriched in the detergent
insoluble membrane fraction which was previously shown to
interact directly with the CD4 co-receptor in lymphocytes [14]
and because we demonstrated in this study that CD81 could in fact
interact with CD3d, a component of the TCR, we hypothesized
that CD81 played an important role in TCR signaling, perhaps
regulating the migration of the TCR into lipid rafts during
signaling. To asses the significance of CD81 in TCR signaling in
an in vivo setting, we utilized CD812/2 mice and as a control,
CD92/2 mice because CD9 is a similar tetraspanin protein.
Although the profile of developing thymocytes in these mice were
documented in previous studies, the impact of the absence of
CD81 on in vivo TCR signaling has never been determined
[16,17]. The cellularity and ratios among the four main
populations of thymocytes (DN, DP, CD4 and CD8SP) and
lymph node cells of either CD812/2 or CD92/2 mice were
similar to WT mice (Figure 4A). Furthermore, the absence of
CD81 or CD9 did not affect the surface expression levels of TCR
on developing thymocytes, mimicking our results in VL3.3M2
thymocyte cell lines in which we downregulated CD81 expression
by shRNA mediated expression arrest (Figure 4B).
Dramatically, the expression of CD5 on ex vivo DP thymocytes
from CD812/2 mice was significantly increased compared to DP
thymocytes from WT and CD92/2 mice, indicating that
although CD81 and CD9 can interact with each other only
CD81 can inhibit in vivo TCR signaling (Figure 4B). We also
assessed the levels of CD69 on ex vivo DP thymocytes from WT,
CD812/2 or CD92/2 mice and found that this marker of
recent thymocyte activation was indistinguishable between these
three populations. Because CD5 expression levels on DP
thymocytes directly reflect the intensity of in vivo TCR signaling,
we conclude that CD81 is a negative regulator of TCR signaling
[18–21]. We confirmed that the CD812/2 mice indeed lacked
surface CD81 expression while retaining surface CD9 expression
on thymocytes and lymphocytes (Figure S4A and S4B).
Figure 3. Stable expression of sh1CD81 downregulates surface CD81 expression and increases TCR mediated activation. (a) GFP
expression before and after puromycin selection in VL3.3M2 cell lines transfected with pLMP encoding CD81 shRNA (sh1CD81) shows the percentage
of cells expressing CD81 shRNA. Shaded histograms show fluorescensce of untransfected VL3.3M2 cells and black lined histograms show GFP
expression in transfected and antibiotic selected cells. (b) CD81 shRNAs decrease surface CD81 expression in stably transfected VL3.3M2 cells. Relative
MFI of CD81 expression on the surface of VL3.3M2 cells that are untransfected (U), or stably transfected with empty pLMP constructs (LMP) or with
pLMP-sh1CD81 constructs (sh1CD81) or single cell cloned stable sh1CD81 expressing clones (clone1 and clone2) was determined by flow cytometry
and plotted as bar graphs. Surface CD81 expression of untransfected VL3.3M2 cells was set to 100. (c) Relative MFI of surface CD69 expression on
VL3.3M2 cells stimulated with plate bound anti-TCRß (1 mg) and anti-CD4 (1 mg). Surface CD69 expression of empty pLMP transfected VL3.3M2 cells
was set to 100.
doi:10.1371/journal.pone.0050396.g003
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Furthermore we assessed the expression of TCR, CD5 and CD69
on CD4+ or CD8+ thymocytes (Figure S4C). While the
expression of these markers between WT and CD812/2 CD4+
thymocytes were indistinguishable, we observed that pre-DP,
immature CD8+ single positive (ISP) cells, characterized by low
TCR and CD5 expression, were lacking in CD812/2mice. Thus
in the absence of CD81 inhibition, thymocytes progress faster
through development.
In order to identify the role of CD81 in TCR signaling on
lymph node T lymphocytes, we purified these cells from either
WT or CD812/2 mice and assessed the upregulation of CD69
upon anti-TCR crosslinking on electronically gated CD4+ or
CD8+ lymphocytes (Figure 5A). Compared to WT lymphocytes
(B10BR), CD812/2 cells responded more robustly to anti-TCRb
crosslinking by upregulating CD69. Specifically, we found a higher
percentage of CD69 positive cells at each concentration of
stimulating anti-TCRb antibody when we compared CD812/2
lymphocytes to WT lymphocytes. This effect was specific to CD4
T lymphocytes, as similar numbers of CD8 T lymphocytes from
CD812/2 and WT mice were signaled to become CD69
positive. Thus, stimulation of the TCR in the absence of CD81
can generate stronger signals than when CD81 is present,
indicating that CD81 normally inhibits TCR signaling.
We next tested whether the lack of CD81 effected events further
downstream of TCR signaling. One of the outcomes of anti-TCR
stimulation of LN T lymphocytes is their proliferation. Thus we
tested whether CD81 deficient lymphocytes proliferated better as a
result of increased TCR signaling, compared to WT lymphocytes
from C57Bl/6 mice. We purified CD4+ lymph node T
lymphocytes, labeled them with the dye CFSE and measured
Figure 4. Inreased signaling intensity in CD812/2 thymocytes. (a) Deficiency of CD81 or CD9 does not affect T lymphocyte development
and thymic cellularity. Thymocytes from B10, CD812/2 and CD92/2mice were analyzed by multicolor flow cytometry. CD4 vs CD8 contour plots of
thymocytes (top row) and lymph node cells (bottom row) are shown. (b) CD81 deficiency increases in vivo signaling intensity in DP thymocytes.
Single parameter histograms of TCRß, CD5 and CD69 expression on electronically gated CD4+CD8+ DP thymocytes from B10 (dashed line), CD812/2
(black line) and CD92/2 (grey line) are shown. The electronic gate used is depicted as a box in the top panels in (a).
doi:10.1371/journal.pone.0050396.g004
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Figure 5. CD81 deficiency increases in vitro TCR signaling intensity in CD4+ lymph node T cells. (a) Deficiency of CD81 results in more
cells that upregulate CD69 upon TCR signaling. Purified LN T cells from B10 or CD812/2 mice were assessed for anti-TCR+anti-CD4 induced up-
regulation of CD69 expression. Left panel: After overnight stimulation with plate bound anti-TCR antibodies, electronically gated CD812/2 CD4 LN T
cells (filled circles) upregulated dramatically more CD69 compared to WT B10 CD4 LN T cells (open circles). Right panel: Stimulation with anti-TCR did
CD81 Inhibits TCR Signaling
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dye dilution upon proliferation of cells stimulated by plate bound
anti-CD3 antibodies (Figure 5B and S5). As compared to
lymphocytes from C57Bl/6 mice, lymphocytes from CD812/2
mice proliferated faster as measured by the percentage of cells that
lose CFSE dye after 40 and 72 hours of stimulation. The
proliferative advantage of CD812/2 CD4+ lymph node T
lymphocytes was more dramatic when stimulated with low doses
of cross-linking anti-CD3 antibody. Thus, limiting TCR signals
and the signaling events that result in CD4+ lymphocyte
proliferation are inhibited by CD81.
Discussion
T lymphocyte signaling is initiated by the engagement of the T
cell receptor complex (TCR) and co-receptors (CD4 or CD8) on
the cell surface of T lymphocytes and cognate antigen presented
on MHC molecules by antigen presenting cells. This engagement
results in the phosphorylation of the TCR signaling subunits and
activation of downstream signaling pathways. In the current study
we focused on the CD3d signaling subunit of the TCR and
identified the tetraspanin membrane protein CD81 as an
interaction partner. CD3d is required for positive selection
signaling at the DP stage of thymocyte development. The lack of
mature SP T lymphocytes in CD3d2/2 mice indicates that the
CD3d subunit is required either for TCR signaling, or for the
expression of this receptor on the surface. On the other hand,
unlike the other CD3 subunits, the CD3d subunit is unique
because pre-TCR signaling controlling the DN to DP transition
can happen in its absence.
In order to identify putative interaction partners of the CD3d
subunit of TCR, we performed a novel membrane based yeast two
hybrid screen. Classical yeast two hybrid screens are limited to
identifying interactions between soluble proteins. However, split
ubiquitin technology allows for the identification of interactions
between membrane anchored bait and prey proteins. In this
system, auxotrophic yeast reporter gene activation was driven by
the translocation of a transcription factor from the yeast cell
plasma membrane to its nucleus. Our bait, CD3d was targeted to
yeast membranes using a SUC2 yeast signal peptide. Because we
conducted our yeast two hybrid screen in yeast cells only
expressing the CD3d subunit and not a full TCR, we predicted
that this protein would be retained in the ER in agreement with
previous studies showing that individual TCR subunits which
assemble into full TCR complexes are retained in the ER [22]. We
also demonstrate that CD3d and CD81 could interact in
mammalian cell lines by co-immunoprecipitation. In order to test
the association between CD3d and CD81 in a setting where CD3d
could assemble into a TCR and be expressed on the cell surface,
we expressed all subunits of the TCR in HEK293T cells. CD3d
continued to interact with CD81 in this cellular setting.
We observed that over-expression of CD81 in either HEK293T
cells expressing TCR or in murine CD4+CD8+ double positive
VL3.3M2 cells resulted in the downregulation of surface TCR
expression. This indicates that either CD81 can interact with TCR
subunits in the ER to regulate assembly and surface expression, or
that elevated levels of CD81 results in the internalization of surface
TCR. While CD81 is clustered to tetraspanin enriched micro-
domains in the cell surface, it also plays a role in the ER. In fact, in
B lymphocytes, the absence of CD81 prevents the exit of the BCR
component CD19 to the B lymphocyte cell surface [16,17,23].
Unlike the role of CD81 in B lymphocytes, in the current study we
find that CD81 overexpression in T cells reduces surface TCR
expression, while both shRNA mediated silencing or genetic
knockout of CD81 does not affect surface TCR. These findings
indicate that CD81 and possibly other tetraspanin proteins
function in the ER by regulating the assembly and surface export
of multisubunit receptors in lymphocytes.
CD81 is a tetraspanin molecule known to function as a specific
membrane dock for signaling proteins in lipid rafts [10]. Antibody
mediated stimulation of T lymphocytes indicates that CD81 is an
in vitro co-stimulator of the TCR [24,25], suggesting that co-
engagement of CD81 with antigen receptors facilitates the
reorganization of the membrane, thereby reducing the threshold
of cell activation. In the current study, we explored whether CD81
cell surface expression levels affect TCR mediated stimulation.
Both in T cell lines and in primary murine T lymphocytes, lower
or absent surface CD81 expression resulted in increased TCR
stimulation as measured by CD69 upregulation. The increase in
TCR signaling in the absence of CD81 in primary lymphocytes
was specific to CD4 SP cells, indicating that the influence of
tetraspanin enriched domains on TCR signaling may differ in
different lymphocyte populations. We infer from this finding that
CD81 proteins in tetraspanin enriched microdomains may be
limiting the access of the TCR to CD4 coreceptors and associated
signaling kinases. CD81 shRNA expressing VL3.3M2 cells
continued to express surface CD81, albeit at lower levels
compared to WT cells. In these cells anti-CD4 and anti-TCR
antibody crosslinking could indeed stimulate CD81low shRNA+
cells better than WT VL3.3M2 cells, a finding consistent with the
faster migration of the TCR into the detergent insoluble
membrane fraction under reduced CD81 expression.
To assess the significance of CD81 in TCR signaling in an in vivo
setting, we utilized CD812/2 mice and as a control, CD92/2
mice because CD9 is also a tetraspanin with a high similarity to
CD81. The absence of CD81 had no effect on the cellularity of the
lymphoid organs and the ratios between CD4 and CD8 thymocyte
populations and lymph node T cells. The most striking effect of the
absence of CD81 was on the levels of CD5 on ex vivo DP
thymocytes. As CD5 levels on DP thymocytes directly reflect the
intensity of in vivo TCR signaling, we conclude that CD81 is a
negative regulator of TCR signaling. This finding is consistent
with increased numbers of CD69 positive CD812/2 lymphocytes
compared to WT cells in in vitro antibody crosslinking experiments.
A role for CD81 in early development of lymphcytes in the thymus
has been proposed [26].
We also tested the effects of the absence of CD81 on the
proliferation properties of signaled lymphocytes. We found that
CD812/2 CD4+ lymph node T cells initiated their proliferation
response to anti-CD3 crosslinking faster when compared to WT
lymphocytes. A previous study found that after 7 days of anti-CD3
stimulation with anti-CD28 co-stimulation, CD812/2 lympho-
cytes proliferated as efficiently as WT lymphocytes [27]. In
contrast to those studies, our stimulation experiments were
conducted for 40 and 72 hours without co-stiumulation, where
we observed a dramatic proliferative advantage of CD81 deficient
lymphocytes, when TCR signaling initiated. Thus, in the absence
not result in a difference between CD812/2 and WT B10 CD8 LN T cells. (b) Frequency of proliferated (.1 cell division) cells after stimulation of
CFSE-labelled purified LN CD4+ cells from B6 and CD812/2 mice. Plots of CFSE dye dilution in CD4 T cells stimulated with plate bound anti-CD3
antibodies indicate the frequency of cells with .1 division. Left plot shows proliferation after 40 hr of stimulation and right plot shows proliferation
after 72 hr of stimulation. At least two mice in each group were analyzed.
doi:10.1371/journal.pone.0050396.g005
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of CD81, lymphocytes can proliferate better if TCR signals are
limiting. In the current study we identify CD81 as an interactor of
TCR subunits and find that TCR signaling on DP thymocytes and
SP lymphocytes is inhibited by CD81 molecules.
Materials and Methods
Split-ubiquitin Yeast Two-hybrid Screening
The split-ubiquitin system and human Jurkat thymus cDNA
libraries were purchased from Dualsystems Biotech (Zurich,
Switzerland). Screening was performed according to manufactur-
er’s protocols (DUALmembrane Kit 3). Briefly, to create the
CD3d bait construct, the sequence encoding mouse CD3d protein
after the signal peptide was amplified using Pfu DNA polymerase
(Fermentas) with overhanging restriction sites. The PCR product
was cloned in frame and downstream of the SUC2 signal peptide
and upstream of the C-terminal half of ubiquitin (Cub) in the
vector pBT3-SUC to create pBT3CD3d, which expresses a
SUC2::CD3d::Cub-LexAVP16 fusion protein and a LEU2
selectable marker. Jurkat thymus cDNA library cloned into
pDSLNx plasmid with a TRP1 selectable marker was used as
the prey vector. Bait and prey vectors were sequentially
transformed into host yeast strain NMY51(MATa his3_200 trp1–
901 leu2–3,112 ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-LacZ
ade2::(lexAop)8-ADE2) using lithium acetate transformation. Clones
encoding proteins that interact with CD3d were recovered from
TRP1-LEU2-HIS3-ADE2- and lacZ- plates. Plasmid DNA was
recovered from yeast cells, and retransformed into the NMY51
yeast strain containing the pBT3CD3d plasmid for a secondary
screen. Clone identity was determined by nucleotide sequencing
and cDNAs were transferred from the pDSLNx plasmid into the
mammalian expression plasmid pHAMex (Dualsytems), in frame
with an N-terminal HA epitope tag.
Plasmids
Full length CD3d cDNA was amplified with primers containing
overhanging restriction sites (Xho I and Hind III) and cloned into
the pcDNA3.1MycHIS plasmid (Invitrogen) in frame with an Myc
epitope tag. shRNAs against CD81 encoded by an XhoI-EcoRI
fragment amplified from a 97 bp long oligonucleotide with two
oligonucleotides (mir30for and mir30rev) were cloned into the
retroviral plasmid MSCV-LTRmiR30-PIG (LMP) (Openbiosys-
tems). To express TCR in HEK293T cells, we used two plasmids,
pMIGII-TCRa (Va11.1)-P2A-TCRb (Vb3)-IRES-GFP and pMI-
GII-CD3d-F2A-CD3c-T2A-CD3e-P2A-CD3f-P2A-IRES-GFP
[28] (kindly provided by D. Vignali). The identity of all plasmids
were confirmed by DNA sequencing.
Cell Culture and Transfection
HEK293T cells were cultured in DMEM supplemented with
10% fetal bovine serum (FBS), at 37uC in a humidified, 5% CO2
incubator and transfected using CaPO4 precipitation with 10 mg
DNA. VL3-3M2 DP thymocyte cell lines (a gift from C. Guidos)
[29] were cultured in RPMI supplemented with 10% FBS and
transfected by electroporation with 15 mg DNA per 0.5–16107
cells in 4 mm electroporation cuvettes with a BTX model 600
electroporator (Harvard Apparatus) using the following settings:
0.4 kV, 100V, 950 mF. For stable transfection, cells were harvested
48 hrs after the transfection and resuspended in RPMI with 1 mg/
ml puromycin and selected in 96 well plates with limiting dilutions.
Immunoprecipitation and Immunoblotting
107 HEK293T cells transiently transfected with mammalian
expression plasmids encoding Myc-CD3d and HA-CD81 were
solubilized in 1% TritonX-100 lysis buffer and immunoprecipi-
tated with 5 mg anti-cMyc (Roche, 11667149001) and 50 ml 1:1
slurry of protein G-sepharose (GE healthcare) or using anti-c-Myc-
agarose conjugates (Sigma IP0020 Kit). Immunoprecipitates were
rocked overnight at 4uC, washed three times with 16 PBS,
resuspended in SDS sample buffer, boiled, resolved by 13% SDS-
PAGE under reducing conditions and transferred to polyvinylidine
difluoride (PVDF) membranes. For immunoblotting, membranes
were blocked in 16PBS containing 0.2% Tween-20 and 5% low-
fat milk powder (Fluka FL70166) and incubated with anti-HA
peroxidase (Roche, 12013819001), washed three times with PBST
visualized with a Super Signal West Dura Extended substrate
(Pierce).
Stimulations
CD4+ or CD8+ LN T lymphocytes were obtained by depletion
of Ig+ cells using Biomag beads (Qiagen) resulting in cell purities
.95%. For anti-TCR and anti-CD4 stimulation, purified lymph
node T cells (26106 cells/ml) or Vl3-3M2 cells (16106 cells/ml)
were plated in 24-well tissue culture plates previously coated (4uC,
overnight) with 0–1000 ng/ml anti-CD4 (GK1.5, BD Biosciences)
and/or anti-TCRb (H57-597, BD Biosciences). Stimulation was
performed 16–24 hr at 37uC and analyzed by CD69 staining. For
CFSE dye dilution assays, CD4 T lymphocytes were purified by
negative selection columns (Miltenyi Biotech mouse CD4+ T cell
Isolation Kit, 130-095-248), 0.2 million cells were loaded with
0.5 mMCFSE for 8 min at room temperature (Invitrogen V12883)
and incubated in 96well plates previously coated (4uC, overnight)
with 0–2000 ng/ml anti-CD3 antibody (clone 145-2C11 (BD
553057) for 40–72 hr at 37uC and analyzed by flow cytometry.
Antibodies and Flow Cytometry
MAbs with the following specificities were used in the present
study: For immunofluorescence to assess the cell surface levels:
CD5 (53-7.3), FITC or PE-TCRb (H57-597), PE-CD4 (GK1.5),
Cy5-CD8a (53.6-7) biotin-CD81 (Eat2, 559518), PE- CD69
(H1.2F3) and PE-conjugated streptavidin (all from BD Biosciences)
and CD8a (CT-CD8a, Caltag). For stimulations: unconjugated
TCRb (H57-597), CD4 (GK1.5). Cells were harvested, stained
with fluorochrome-conjugated antibodies by incubating on ice for
30 min and analyzed by flow cytometry on a FACSCanto or
FACSCalibur system (Becton Dickinson). Dead cells were
excluded by forward light scatter and propidium iodide (PI) or
7-aminoactinomycin D (7-AAD) staining. Analysis was performed
using FlowJo 9.5.2 software.
Mice
B10.Br, CD812/2 [16] and CD92/2 [30] mice in the
B10.Br background were bred in the colony of the Experimental
Immunology Branch. CD812/2 animals used for proliferation
experiments were backcrossed in this colony to the C57Bl/6
background and were compared to C57Bl/6 mice. Animal
experiments were approved by the National Cancer Institute
Animal Care and Use Committee and were performed in the
Experimental Immunology Branch, National Cancer Institute,
Bethesda, MD. All mice used in this study were cared for in
accordance with National Institutes of Health guidelines.
Oligonucleotides used in this study
The following oligonucleotides were used for amplification.
Restriction enzyme sites used for cloning are shown in bold
lettering.
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CD81-3 59-TGC TGT TGA CAG TGA GCG CGC AGC
CAT TGT GGT AGC TGT CTA GTG AAG CCA CAG ATG
TAG ACA GCT ACC ACA ATG GCT GCA TGC CTA CTG
CCT CGG A-39
CD81-2 59-TGC TGT TGA CAG TGA GCG ATG TCA
TTA TGA TCT TTG AGA TTA GTG AAG CCA CAG ATG
TAA TCT CAA AGA TCA TAA TGA CAG TGC CTA CTG
CCT CGG A-39
CD81-1 59-TGC TGT TGA CAG TGA GCG CGC TGT
CAT TAT GAT CTT TGA GTA GTG AAG CCA CAG ATG
TAC TCA AAG ATC ATA ATG ACA GCT TGC CTA CTG
CCT CGG A-39
mir30for 59-CAG AAG GCT CGA GAA GGT ATA TTG
CTG TTG ACA GTG AGC G-39
mir30rev 59-CTA AAG TAG CCC CTT GAA TTC CGA
GGC AGT AGG CA-39
Sfi-d-F1 59-CCG GGC CAT TAC GGC CTT CAA GGT
ACA AGT GAC CG-39
Sfi-d-R 59-GAC GGC CGA GCC GGC CTT AGA TTT
CTT GTT CCG GGG-39
FRET-d-F 59-CCG CTC GAG GCC ACC ATG GAA CAC
AGC GGG ATT CTG-39
FRET-d-R 59-CCC AAG CTT AGA TTT CTT GTT CCG
GGG-39
Supporting Information
Figure S1 The split ubiquitin membrane yeast two
hybrid system. A bait protein (X) is fused to the C-terminal
domain of human ubiquitin protein (Cub) and a LexA/VP16
transcription factor. Interaction of this bait with a prey (Y)
encoded by a human Jurkat T cell cDNA library fused to the N-
terminal domain of ubiquitin (Nub) results in the reconstitution of
ubiquitin activity. The interaction dependent close proximity of
Cub and Nub is recognized by yeast ubiquitin specific proteases
(UBPs) which cleave the LexA/VP16 domain, setting it free to
translocate to the yeast nucleus which results in the expression of
the HIS3 and ADE2 auxotrophic markers and LacZ reporter
genes controlled by LexA binding sites.
(TIF)
Figure S2 CD81 interacts with CD3d in the presence
and absence of surface TCR expression. (a) De novo TCR
expression in HEK293 cells. HEK293 cells were transfected with
two plasmids encoding TCRa+TCRb and CD3d+CD3c+
CD3e+TCRf and analyzed by flow cytometry at the indicated
times after transfection for surface TCR expression by PE
conjugated anti-TCRb staining. Polycistronic expression plasmids
contained and IRES-EGFP reporter, and the TCR expression on
GFP+ cells is shown. (b) CD81 interacts with CD3d. Combina-
tions of plasmids used for transfection are indicated by (+). NP-40
lysates of transfected cells were prepared 40 hours after transfec-
tion (corresponding to peak surface TCR expression) and
immunoprecipitated with anti-Myc epitope Ab and blotted for
anti-HA epitope Ab. Lysates were also blotted directly with anti-
HA epitope Ab to show the expression of HA-CD81 in transfected
cells.
(TIF)
Figure S3 Stable expression of sh1CD81 increases TCR
mediated activation without affecting surface TCR
expression. (a) CD81 shRNAs does not affect surface TCR
expression in stably transfected VL3.3M2 cells. Relative MFI of
TCRb expression on the surface of VL3.3M2 cells that are
untransfected (U), or stably transfected with empty pLMP
constructs (LMP) or with pLMP-sh1CD81 constructs (sh1CD81)
or single cell cloned stable sh1CD81 expressing clones (clone1 and
clone2) was determined by flow cytometry and plotted as bar
graphs. Surface TCRb expression of untransfected VL3.3M2 cells
was set to 100. (b) Surface CD69 expression activated by anti-
TCR+anti-CD4 co-crosslinking is inversely proportional to the
level of surface CD81 expression. VL3.3M2 cells were crosslinked
with plate bound anti-TCR+anti-CD4 antibodies and MFI of
surface CD69 expression on empty LMP transfected (squares),
sh1CD81 expressing (circles) and single cell cloned high sh1CD81
expressing clone 2 cells (triangles) were plotted for increasing
antibody concentrations.
(TIF)
Figure S4 Surface expression of CD81, CD9, TCR, CD5
and CD69 on the surface of CD812/2 and CD92/2
thymocytes and lymph node cells. (a) Surface CD81 and
CD9 expression on CD812/2 (black histograms) and CD92/2
(grey histograms) on DP thymocytes shown in the gate defined in
Figure 4. Isotype control staining is shown as a shaded histogram.
(b) Surface CD81 and CD9 expression on CD812/2 (black
histograms) and CD92/2 (grey histograms) on LN cells. (c)
Surface TCRb, CD5 and CD69 expression on CD812/2 (black
histograms) and CD92/2 (grey histograms) on CD4 (top row)
and CD8 (bottom row) SP thymocytes.
(TIF)
Figure S5 CD812/2 LN CD4+ lymphocytes proliferate
faster than WT cells. Frequency of proliferated (.1 cell
division) cells after stimulation of CFSE-labeled purified LN CD4+
cells from B6 and CD812/2 mice. Histograms show CFSE
expression in stimulated CD4 T cells and numbers in the left gate
indicate the frequency of cells with.1 division and the numbers in
the right gate indicate un-proliferated cells.
(TIF)
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